AAREYDRUGS

Aarey Drugs & Pharmaceuticals Share Price

₹57.66 -2.52 (-4.19%)

14 Nov, 2024 09:13

SIP TrendupStart SIP in AAREYDRUGS

Start SIP

Performance

  • Low
  • ₹57
  • High
  • ₹61
  • 52 Week Low
  • ₹37
  • 52 Week High
  • ₹75
  • Open Price₹61
  • Previous Close₹60
  • Volume23,112

Investment Returns

  • Over 1 Month -7.25%
  • Over 3 Month + 3.78%
  • Over 6 Month + 18.64%
  • Over 1 Year + 15.78%
SIP Lightning

Smart Investing Starts Here Start SIP with Aarey Drugs & Pharmaceuticals for Steady Growth!

Invest Now

Aarey Drugs & Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 31.5
  • PEG Ratio
  • 1.2
  • Market Cap Cr
  • 164
  • P/B Ratio
  • 1.2
  • Average True Range
  • 3.48
  • EPS
  • 2.34
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.77
  • RSI
  • 36.72
  • MFI
  • 41.64

Aarey Drugs & Pharmaceuticals Technicals

EMA & SMA

Current Price
₹57.66
-2.52 (-4.19%)
pointer
  • stock-down_img
  • Bullish Moving Average 3
  • stock-up_img
  • Bearish Moving Average 13
  • 20 Day
  • ₹62.27
  • 50 Day
  • ₹62.67
  • 100 Day
  • ₹60.22
  • 200 Day
  • ₹55.78

Resistance and Support

58.61 Pivot Speed
  • R3 63.88
  • R2 62.44
  • R1 60.05
  • S1 56.22
  • S2 54.78
  • S3 52.39

What's your outlook on Aarey Drugs & Pharmaceuticals?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Aarey Drugs & Pharms. has an operating revenue of Rs. 471.57 Cr. on a trailing 12-month basis. An annual revenue de-growth of -5% needs improvement, Pre-tax margin of 1% needs improvement, ROE of 3% is fair but needs improvement. The company has a reasonable debt to equity of 2%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and around 11% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 19% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 81 which is a GOOD score indicating consistency in earnings, a RS Rating of 60 which is FAIR indicating the recent price performance, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 40 indicates it belongs to a strong industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Aarey Drugs & Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-14 Quarterly Results
2024-10-01 Others
2024-08-14 Quarterly Results
2024-05-30 Audited Results
2024-03-27 Others Inter alia, to consider the allotment of Equity Shares and Warrants.

Aarey Drugs & Pharmaceuticals F&O

Aarey Drugs & Pharmaceuticals Shareholding Pattern

45.44%
2.75%
47.57%
4.24%

About Aarey Drugs & Pharmaceuticals

  • NSE Symbol
  • AAREYDRUGS
  • BSE Symbol
  • 524412
  • Chairman & Managing Director
  • Mr. Mihir R Ghatalia
  • ISIN
  • INE198H01019

Similar Stocks to Aarey Drugs & Pharmaceuticals

Aarey Drugs & Pharmaceuticals FAQs

Aarey Drugs & Pharmaceuticals share price is ₹57 As on 14 November, 2024 | 08:59

The Market Cap of Aarey Drugs & Pharmaceuticals is ₹163.5 Cr As on 14 November, 2024 | 08:59

The P/E ratio of Aarey Drugs & Pharmaceuticals is 31.5 As on 14 November, 2024 | 08:59

The PB ratio of Aarey Drugs & Pharmaceuticals is 1.2 As on 14 November, 2024 | 08:59

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23